Tag: immunotherapy
Click to read the study in the European Journal of Cancer.
Click to read the study in The Lancet Oncology.
Click to see previously reported survival outcomes from the same cohort.
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in Melanoma Research.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy.
2. Patients treated with cemiplimab monotherapy reported fewer grade 3-4 adverse events.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Among patients with advanced non-small-cell lung cancer (NSCLC), a large proportion test positive for programmed cell death...
Click to read the study in European Journal of Cancer
1. Rituximab was found to significantly reduce median time to remission in new-onset myasthenia gravis.
2. Rituximab appeared to outperform conventional immunosuppressant therapy in terms of need for rescue therapy and adverse effects resulting in discontinuation.
Evidence Rating Level: 2 (Good)
Myasthenia gravis (MG) is a serious neuromuscular disease, resulting from an autoreactive humoral...
Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic malignancies, however, there are limited data to support this approach in the management of epithelial cancers. Human papillomavirus (HPV)-associated epithelial cancers express viral E6 and E7 oncoproteins, which are...
1. IL-2 is a central cytokine that enhances the immune response, with considerable potential for the treatment of cancer.
2. A mimic of IL-2 binds its receptor more tightly and more potently than the natural cytokine, without adverse effects, in mouse models of melanoma and colon cancer.
Evidence Rating Level: 2...